Literature DB >> 29415577

Janus kinase inhibition and symptom control in myeloproliferative neoplasms.

Prithviraj Bose1, Mahesh Swaminathan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29415577      PMCID： PMC6329289          DOI： 10.1080/03007995.2018.1438999

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN： 0300-7995            Impact factor:   2.580


× No keyword cloud information.
  24 in total

1.  A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Authors:  Alessandro M Vannucchi; Hagop M Kantarjian; Jean-Jacques Kiladjian; Jason Gotlib; Francisco Cervantes; Ruben A Mesa; Nicholas J Sarlis; Wei Peng; Victor Sandor; Prashanth Gopalakrishna; Abdel Hmissi; Viktoriya Stalbovskaya; Vikas Gupta; Claire Harrison; Srdan Verstovsek
Journal:  Haematologica       Date:  2015-06-11       Impact factor: 9.941

2.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

3.  Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Ruben Mesa; Catriona Jamieson; Ravi Bhatia; Michael W Deininger; Aaron T Gerds; Ivana Gojo; Jason Gotlib; Krishna Gundabolu; Gabriela Hobbs; Rebecca B Klisovic; Patricia Kropf; Sanjay R Mohan; Stephen Oh; Eric Padron; Nikolai Podoltsev; Daniel A Pollyea; Raajit Rampal; Lindsay A M Rein; Bart Scott; David S Snyder; Brady L Stein; Srdan Verstovsek; Martha Wadleigh; Eunice S Wang; Mary Anne Bergman; Kristina M Gregory; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-12       Impact factor: 11.908

4.  Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Authors:  Srdan Verstovsek; Francesco Passamonti; Alessandro Rambaldi; Giovanni Barosi; Elisa Rumi; Elisabetta Gattoni; Lisa Pieri; Huiling Zhen; Muriel Granier; Albert Assad; Mario Cazzola; Hagop M Kantarjian; Tiziano Barbui; Alessandro M Vannucchi
Journal:  Blood       Date:  2017-08-21       Impact factor: 22.113

5.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Authors:  Ayalew Tefferi; Francisco Cervantes; Ruben Mesa; Francesco Passamonti; Srdan Verstovsek; Alessandro M Vannucchi; Jason Gotlib; Brigitte Dupriez; Animesh Pardanani; Claire Harrison; Ronald Hoffman; Heinz Gisslinger; Nicolaus Kröger; Juergen Thiele; Tiziano Barbui; Giovanni Barosi
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

6.  Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Authors:  Francesco Passamonti; Martin Griesshammer; Francesca Palandri; Miklos Egyed; Giulia Benevolo; Timothy Devos; Jeannie Callum; Alessandro M Vannucchi; Serdar Sivgin; Caroline Bensasson; Mahmudul Khan; Nadjat Mounedji; Guray Saydam
Journal:  Lancet Oncol       Date:  2016-12-02       Impact factor: 41.316

7.  Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Authors:  Claire N Harrison; Adam J Mead; Anesh Panchal; Sonia Fox; Christina Yap; Emmanouela Gbandi; Aimee Houlton; Samah Alimam; Joanne Ewing; Marion Wood; Frederick Chen; Jason Coppell; Nicki Panoskaltsis; Steven Knapper; Sahra Ali; Angela Hamblin; Robyn Scherber; Amylou C Dueck; Nicholas C P Cross; Ruben Mesa; Mary Frances McMullin
Journal:  Blood       Date:  2017-08-09       Impact factor: 22.113

8.  Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

Authors:  Kate J Newberry; Keyur Patel; Lucia Masarova; Rajyalakshmi Luthra; Taghi Manshouri; Elias Jabbour; Prithviraj Bose; Naval Daver; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2017-07-03       Impact factor: 22.113

9.  Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

Authors:  Carole B Miller; Rami S Komrokji; Ruben A Mesa; William Sun; Michael Montgomery; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-05-12

10.  Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.

Authors:  Ruben Mesa; Carole B Miller; Maureen Thyne; James Mangan; Sara Goldberger; Salman Fazal; Xiaomei Ma; Wendy Wilson; Dilan C Paranagama; David G Dubinski; John Boyle; John O Mascarenhas
Journal:  BMC Cancer       Date:  2016-02-27       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.